New Drug Helps Diabetics Lose 37 Pounds in Study

People with type 2 diabetes just got some incredible news from the world of medical research.

A new medication called retatrutide helped trial participants lose an average of up to 36.6 pounds over 40 weeks while also lowering their blood sugar levels, according to drugmaker Eli Lilly. The results mark a major milestone for a promising new class of weight loss drugs called GLP-3 agonists.

Unlike existing medications that target just one or two hormone receptors that control hunger, retatrutide targets three different receptors at once. This triple action approach appears to make it more effective than drugs currently on the market.

The phase 3 clinical trial showed participants experienced a significant 1.7 to 2 percent decrease in A1C, a key measure doctors use to track average blood sugar levels over time. Those taking the highest dose of 12 milligrams saw the most dramatic results.

"Overall, this is incredibly exciting," says Dr. Rozalina McCoy, an endocrinologist at the University of Maryland. She notes this is the first triple agonist drug tested this way, and researchers weren't sure it would outperform existing treatments.

Dr. Daniel Drucker from the University of Toronto called the data "very solid" with "excellent" weight loss and blood sugar results. The safety profile matched other established medications in this growing drug class, which he found reassuring for future patients.

Why This Inspires

What makes this breakthrough so meaningful is the timing. For years, people struggling with type 2 diabetes and obesity had limited options that often came with difficult side effects or modest results.

Now researchers are building what Dr. McCoy calls "a growing tool kit" to tackle these conditions. The medication isn't perfect—some participants experienced nausea, diarrhea, and vomiting, and a small percentage reported painful sensations that need further study.

But the promise is real. Not everyone will need such rapid weight loss, and doctors will monitor patients carefully for any issues with quick blood sugar drops.

The most important challenge ahead is making sure patients can actually access these new medications affordably and safely. "We are in a new era that we have been waiting for," Dr. McCoy says.

For millions of Americans managing diabetes and weight concerns, that new era could mean finally having treatments that work with their bodies instead of against them.